The acquisition of ATDBio adds important platform solutions to Biotage within DNA and RNA oligonucleotide synthesis and purification.
Pulse Scientific is located on the shores of Lake Ontario between Toronto and Niagara Falls in Burlington, Ontario
Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress.
FCS Express expands the flow cytometry solutions within the Insightful Science platform, enabling world-class data-driven scientific research in academia and biopharma and clinical analysis in regulated enterprise environments. Insightful Science is the leading end-to-end scientific research platform with both the broadest and deepest scientific capabilities across chemistry and biology. The unique platform accelerates innovation and drug discovery by producing a seamless flow of clean and trustworthy data throughout labs.
Under the terms of the agreement, Inovalon stockholders will receive $41.00 per share in cash for each share of Class A Common Stock or Class B Common Stock, representing a 25.3% premium over the closing price of Inovalon Class A Common Stock on July 26, 2021, the last unaffected trading day prior to media speculation regarding a potential transaction, and a 24.4% premium over the volume-weighted average price of the Company’s shares over the 30 trading days leading up to the unaffected trading day.
The Bioinfogate OFF-X™ portal is a cutting-edge safety intelligence solution aimed at empowering pharmaceutical organizations to identify toxicology and safety signals, mitigate safety liabilities and de-risk early-stage assets.
Ken Reali, Chief Executive Officer of Bioventus, stated, “We are excited to further establish Bioventus as a differentiated, growth-focused medical technology company with deep and broad capabilities across a range of care settings and specialties. We believe this acquisition will accelerate our growth opportunities, enhance our double-digit revenue growth, and provide a significant opportunity for long-term margin expansion. We believe the combination with Misonix will create significant value for our shareholders and enable us to better serve our customers with more comprehensive solutions and a broader portfolio. The new Bioventus will also unlock meaningful growth opportunities for the employees of both organizations.”
Arch operates two divisions: the laboratory-based analytical services division, which directly supports drug development and new product regulatory approval cycles, and the technical laboratory solutions division, which supports a wide range of third-party laboratories.
Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Absci is a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. This acquisition adds antibody and target discovery technology to Absci's platform for therapeutic protein design and biomanufacturing optimization.
The acquisition aligns with PureTech’s strategy to advance a Wholly Owned Pipeline designed to harness key immunological, fibrotic and lymphatic system mechanisms to treat serious diseases with significant unmet needs.
12Page 1 of 2